Democratic lawmakers say former President Donald Trump increased investments in pharmaceutical companies that received favorable treatment under a Medicare-related provision in the Republicans’ 2025 tax and spending law. A report described holdings tied to drugmakers that benefit from Medicare exemptions, alleging the investments grew around the policy change.
PBS NewsHour reports that the Democrats’ findings show Trump’s pharmaceutical stock holdings rose from a maximum reported value of about $1.7 million in 2024 to as much as $56.2 million by the end of 2025. Newsweek similarly cites figures suggesting up to $39.1 million was held in companies benefiting from the relevant provision, framing the claim as an example of financial exposure coinciding with the legislation.
The outlets present the same core allegation—growth in drug-sector holdings alongside Medicare exemptions—while emphasizing different reported dollar ranges and timeframes based on the Democrats’ analysis of disclosed investment information.
